CXCL10/IP-10/CRG-2 Antibody (134013)

Recombinant Mouse CXCL10/CRG‑2 (Catalog # 466-CR) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse CXCL10/CRG‑2 (0.5 µg/mL) is neutralized (green line) by increasing concentrations of Mouse CXCL10/CRG‑2 Monoclonal Antibody (Catalog # MAB466). The ND50 is typically 10-40 µg/mL.

Anti-CXCL10 treatment in atherosclerosis susceptible mice results in a change into a more stable lesion phenotype. A flow-altering device around the common carotid artery induced atherosclerosis in ApoE−/− mice. From week 1 to 4 of lesion development, a bioactivity-neutralizing anti-CXCL10 antibody was injected. After 9 weeks, lesions were compared to untreated controls by histology. The pictures show representative histological sections of treated and control mice. All photographs have been made with the same magnification (100x). Scale bars are provided in (e) and represent 100 μm. Data in bar diagrams are the mean values ± SD of at least 8 sections from at least 10 different animals per group. CXCL10 inhibition resulted in a more stable morphology evidenced by unchanged amounts of lesion macrophages (a), increased amounts of collagen (b), decreased macrophage activation (c), increased numbers of SMC (d), and reduced necrotic core size (e). *P < 0.05, **P < 0.01. MHC-II: Major Histocompatibility Complex Class II, SMC: smooth muscle cell. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/22164344), licensed under a CC-BY license. Not internally tested by R&D Systems.

Anti-CXCL10 treatment in atherosclerosis susceptible mice results in a change into a more stable lesion phenotype. A flow-altering device around the common carotid artery induced atherosclerosis in ApoE−/− mice. From week 1 to 4 of lesion development, a bioactivity-neutralizing anti-CXCL10 antibody was injected. After 9 weeks, lesions were compared to untreated controls by histology. The pictures show representative histological sections of treated and control mice. All photographs have been made with the same magnification (100x). Scale bars are provided in (e) and represent 100 μm. Data in bar diagrams are the mean values ± SD of at least 8 sections from at least 10 different animals per group. CXCL10 inhibition resulted in a more stable morphology evidenced by unchanged amounts of lesion macrophages (a), increased amounts of collagen (b), decreased macrophage activation (c), increased numbers of SMC (d), and reduced necrotic core size (e). *P < 0.05, **P < 0.01. MHC-II: Major Histocompatibility Complex Class II, SMC: smooth muscle cell. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/22164344), licensed under a CC-BY license. Not internally tested by R&D Systems.

Anti-CXCL10 treatment in atherosclerosis susceptible mice results in a change into a more stable lesion phenotype. A flow-altering device around the common carotid artery induced atherosclerosis in ApoE−/− mice. From week 1 to 4 of lesion development, a bioactivity-neutralizing anti-CXCL10 antibody was injected. After 9 weeks, lesions were compared to untreated controls by histology. The pictures show representative histological sections of treated and control mice. All photographs have been made with the same magnification (100x). Scale bars are provided in (e) and represent 100 μm. Data in bar diagrams are the mean values ± SD of at least 8 sections from at least 10 different animals per group. CXCL10 inhibition resulted in a more stable morphology evidenced by unchanged amounts of lesion macrophages (a), increased amounts of collagen (b), decreased macrophage activation (c), increased numbers of SMC (d), and reduced necrotic core size (e). *P < 0.05, **P < 0.01. MHC-II: Major Histocompatibility Complex Class II, SMC: smooth muscle cell. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/22164344), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Mu
• Applications: WB, B/N, ELISA(Cap)
• Clone: 134013
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

CXCL10/IP-10/CRG-2 Antibody (134013) Summary

• Immunogen: E. coli-derived recombinant mouse CXCL10/IP-10/CRG-2
  Ile22-Pro98
  Accession # P17515
• Specificity: Detects mouse CXCL10/IP-10/CRG-2 in ELISAs and Western blots. In Western blots, this antibody does not cross-react with recombinant human (rh) CXCL1, 2, 3, 5, 6, 7, 9, 10, 11, 12/SDF-1 alpha , 12/SDF-1 beta , 13, rmCXCL1, 2, 6, 9, 11, 12/SDF-1 alpha , 13, rpCXCL8, rrCXCL1, 3/CINC-2 alpha , 3/CINC-2 beta
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: Cxcl10
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 10-40 ug/mL
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Mouse CXCL10/IP-10/CRG-2 Biotinylated Antibody (Catalog number BAF466)
  Standard: Recombinant Mouse CXCL10/IP-10/CRG-2 (Catalog number 466-CR)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL10/IP-10/CRG-2 Antibody (134013)

• C7
• chemokine (C-X-C motif) ligand 10
• CRG2
• CRG-2
• CXCL10
• gIP-10
• IFI10
• INP10
• IP-10
• mob-1
• SCYB10

Background

The gene for CRG-2, a mouse homolog of human IP-10, was originally identified as an immediate early gene induced in response to macrophage activation. It has since been shown that CRG-2 mRNA is induced by alpha / beta / gamma -interferons and by lipopolysaccharide in macrophages, astrocytes and microglia. Human IP-10 was also shown to be expressed in activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. Mouse CRG-2 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted mature protein. Mature CRG-2 shares approximately 67% amino acid sequence identity with human IP-10. The amino acid sequence of CRG-2 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CRG-2 has been shown to be a chemoattractant for activated T-lymphocytes. Recently, human IP-10 has also been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent anti-tumor effect. A chemokine receptor specific for IP-10 and MIG (CXCR3) has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
2. Vanguri, P. (1996) J. Neuroimmunol. 56:35.
3. Sgadari, C. et al. (1996) Blood, 87:3877.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL10/IP-10/CRG-2 Antibody (MAB466)(21)

Publications using MAB466

• C Peng, G Tu, J Wang, Y Wang, P Wu, L Yu, Z Li, X Yu MLKL signaling regulates macrophage polarization in acute pancreatitis through CXCL10 Cell Death & Disease, 2023-02-24;14(2):155. 2023-02-24 [PMID: 36828808] (Neutralization, Mouse)
• Kuo Jiang, Qianfeng Zhang, Yong Fan, Jia Li, Jitao Zhang, Wentao Wang et al. MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma Cell Death Discovery 2022-03-15 [PMID: 35292660] (Neutralization, Mouse)
• S Hu, Y Gao, R Gao, Y Wang, Y Qu, J Yang, X Wei, F Zhang, J Ge The selective STING inhibitor H-151 preserves myocardial function and ameliorates cardiac fibrosis in murine myocardial infarction International immunopharmacology, 2022-03-09;107(0):108658. 2022-03-09 [PMID: 35278833] (Neutralization, Mouse)
• Shi-Long Zhang, Bing Han, Yu-Qin Mao, Zheng-Yan Zhang, Zhan-Ming Li, Chao-Yue Kong et al. Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice Gut Microbes 2022-12-31 [PMID: 35259052]
• MA Mawhin, RG Bright, JD Fourre, EI Vloumidi, J Tomlinson, A Sardini, CD Pusey, KJ Woollard Chronic kidney disease mediates cardiac dysfunction associated with increased resident cardiac macrophages Bmc Nephrology, 2022-01-28;23(1):47. 2022-01-28 [PMID: 35090403] (In Vivo, Mouse)
• MH Mursalin, PS Coburn, FC Miller, ET Livingston, R Astley, MC Callegan C-X-C Chemokines Influence Intraocular Inflammation During Bacillus Endophthalmitis Investigative Ophthalmology & Visual Science, 2021-11-01;62(14):14. 2021-11-01 [PMID: 34784411] (Neutralization, Mouse)
• Veethika Pandey, Alicia Fleming-Martinez, Ligia Bastea, Heike R Doeppler, Jillian Eisenhauer, Tam Le et al. CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions eLife 2021-07-30 [PMID: 34328416]
• Lingfei Jia, Yilun Wang, Cun‐Yu Wang circFAT1 Promotes Cancer Stemness and Immune Evasion by Promoting STAT3 Activation Advanced Science 2021-07-01 [PMID: 34258151]
• Jorge Luis Galeano Niño, Sophie V Pageon, Szun S Tay, Feyza Colakoglu, Daryan Kempe, Jack Hywood et al. Cytotoxic T cells swarm by homotypic chemokine signalling eLife 2020-10-13 [PMID: 33046212]
• QF Zhang, J Li, K Jiang, R Wang, JL Ge, H Yang, SJ Liu, LT Jia, L Wang, BL Chen CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner Theranostics, 2020-08-25;10(23):10619-10633. 2020-08-25 [PMID: 32929370] (Migration Assay, Mouse)
• Z Pang, R Raudonis, C McCormick, Z Cheng Early growth response 1 deficiency protects host against Pseudomonas aeruginosa lung infection Infect. Immun., 2019-12-17;0(0):. 2019-12-17 [PMID: 31611276] (ELISA Capture, Mouse)
• M William, LP Leroux, V Chaparro, TE Graber, T Alain, M Jaramillo Translational repression of Ccl5 and Cxcl10 by 4E-BP1 and 4E-BP2 restrains the ability of mouse macrophages to induce migration of activated T�cells Eur. J. Immunol., 2019-05-06;0(0):. 2019-05-06 [PMID: 31032899] (Neutralization, Mouse)
• AK Verma, TS Waghmare, GR Jachak, SC Philkhana, DS Reddy, A Basu Nitrosporeusine analogue ameliorates Chandipura virus induced inflammatory response in CNS via NF?b inactivation in microglia PLoS Negl Trop Dis, 2018-07-12;12(7):e0006648. 2018-07-12 [PMID: 30001342] (ELISA Development (Capture), Mouse)
• Zhang X, Wu WK, Xu W et al. CXC Motif Chemokine 10 Impairs Autophagy and Autolysosome Formation in Non-alcoholic Steatohepatitis Theranostics. [PMID: 28824718]
• R Lv, J Zhao, M Lei, D Xiao, Y Yu, J Xie IL-33 Attenuates Sepsis by Inhibiting IL-17 Receptor Signaling through Upregulation of SOCS3 Cell. Physiol. Biochem., 2017-08-09;42(5):1961-1972. 2017-08-09 [PMID: 28793286] (ELISA Development (Capture), Mouse)
• Ioannidis L, Nie C, Ly A, Ryg-Cornejo V, Chiu C, Hansen D Monocyte- and Neutrophil-Derived CXCL10 Impairs Efficient Control of Blood-Stage Malaria Infection and Promotes Severe Disease. J Immunol, 2015-12-30;196(3):1227-38. 2015-12-30 [PMID: 26718341] (ELISA Development (Capture), Mouse)
• Barreira da Silva R, Laird M, Yatim N, Fiette L, Ingersoll M, Albert M Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol, 2015-06-15;16(8):850-8. 2015-06-15 [PMID: 26075911] (ELISA Development (Capture), Neutralization, Mouse)
• Katarina Radulovic, Valerio Rossini, Calin Manta, Karlheinz Holzmann, Hans A. Kestler, Jan Hendrik Niess The Early Activation Marker CD69 Regulates the Expression of Chemokines and CD4 T Cell Accumulation in Intestine PLoS ONE 2013-06-12 [PMID: 23776480]
• Dolf Segers, Jonathan A. Lipton, Pieter J. M. Leenen, Caroline Cheng, Dennie Tempel, Gerard Pasterkamp et al. Atherosclerotic Plaque Stability Is Affected by the Chemokine CXCL10 in Both Mice and Humans International Journal of Inflammation 2011-11-13 [PMID: 22164344]
• Samantha R. Stubblefield Park, Mi Widness, Alan D. Levine, Catherine E. Patterson T Cell-, Interleukin-12-, and Gamma Interferon-Driven Viral Clearance in Measles Virus-Infected Brain Tissue Journal of Virology 2011-04-01 [PMID: 21270150]
• Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol., 2008-02-19;83(5):1136-44. 2008-02-19 [PMID: 18285406] (Flow Cytometry, Mouse)

Bioinformatics

• Gene Symbol: Cxcl10
• Uniprot:
  • P17515()